Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05529316 · ClinicalTrials.gov registry record · Phase 2
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
A Phase 2 study of Advanced Melanoma, sponsored by Agenus.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT05529316 is a Phase 2 study of Advanced Melanoma that is active but no longer recruiting, run by Agenus. The registered enrollment target is 150 participants, roughly in line with the 165-participant average among 21 other Advanced Melanoma trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT05529316, a Phase 2 study of Advanced Melanoma, is active but no longer recruiting, sponsored by Agenus.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.
Conditions Studied
Interventions
- DRUG Balstilimab
- DRUG Botensilimab
Study Locations (20)
Other
- Universitair Ziekenhuis Brussel - Jette
- Oncosite - Centro de Pesquisa Clinica Em Oncologia - Ijuí
- Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho - Jaú
- Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa - Porto Alegre
- INCA II - Instituto Nacional de Cancer Jose Alencar Gomes da Silva - Rio de Janeiro
- Hospital Sirio Libanes - São Paulo
- Real e Benemerita Associaçao Portuguesa de Beneficencia - A Beneficencia Portuguesa de Sao Paulo - São Paulo
- Hospital A.C. Camargo Cancer Center - São Paulo
- CHU Amiens Picardie - Hopital Sud - Amiens
- CHU Grenoble-Alpes - Hopital Michallon - La Tronche
- Centre Leon Berard - Lyon
- CHU de Nantes - Nantes
- AP-HP Hopital Saint-Louis - Paris
California
- Virginia K. Crosson Cancer Center at St. Jude Medical Center - Fullerton
- Providence Saint John's Health Center - Santa Monica
Arizona
- Scottsdale Healthcare Hospitals DBA HonorHealth - Scottsdale
Connecticut
- Yale University School of Medicine - Yale Cancer Center - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Massachusetts
- Dana-Farber Cancer Institute - Boston
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05529316
The ClinicalTrials.gov registry entry for NCT05529316 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 165-participant average among 21 other Advanced Melanoma trials with a reported enrollment target. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Balstilimab is the first listed.
NCT05529316 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05529316 about?
NCT05529316 is a clinical study titled "A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma". This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.
What is the current status of trial NCT05529316?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2022-12-12. Estimated completion is 2028-02.
What conditions does trial NCT05529316 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT05529316?
The interventions under investigation include: Balstilimab (DRUG), Botensilimab (DRUG).
Who is sponsoring clinical trial NCT05529316?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05529316 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
RECRUITING · Phase 2
-
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
RECRUITING · Phase 2
-
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.